FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131232783> ?p ?o ?g. }

• W2131232783 endingPage "2703" @default.
• W2131232783 startingPage "2695" @default.
• W2131232783 abstract "Abstract Purpose: Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody that binds human Dll4 and disrupts Notch-mediated signaling. The main objectives of this trial were to determine the safety, dose-limiting toxicities (DLT), pharmacokinetics (PK), and recommended phase II dose (RP2D) of enoticumab. Experimental Design: Enoticumab was administered intravenously, with dose escalations from 0.25 to 4 mg/kg every 3 weeks (Q3W) and 0.75 to 3 mg/kg every 2 weeks (Q2W). Results: Of 53 enrolled patients, 31 patients were treated Q3W and 22 patients were treated Q2W. Two DLTs occurred: grade 3 nausea (0.5 mg/kg Q3W) and grade 3 abdominal pain (1 mg/kg Q2W). An MTD was not reached on either schedule. The most frequent adverse events (AE) were fatigue, nausea, vomiting, hypertension, headache, and anorexia. Six treatment-related serious AEs were reported in 4 patients: brain natriuretic peptide (BNP) increase (0.25 mg/kg Q3W, Gr1), troponin I increase (4 mg/kg Q3W, Gr3), right ventricular dysfunction and pulmonary hypertension (1.5 mg/kg Q2W, both Gr3), and left ventricular dysfunction and pulmonary hypertension (3 mg/kg Q2W, both Gr3). Enoticumab was characterized by nonlinear, target-mediated PK, and had a terminal half-life of 8 to 9 days. With multiple Q2W or Q3W dosing, accumulation was not observed. Antitumor activity included two partial responses (non–small cell lung cancer bronchoalveolar-type with a β-catenin mutation, and ovarian cancer) and 16 patients with stable disease (3&gt; 6 months). Conclusions: Enoticumab was tolerated, with RP2D of 4 mg/kg Q3W and 3 mg/kg Q2W based on PK profile and clinical activity. Responses and SD were noted in ovarian cancer and other solid tumors. Clin Cancer Res; 21(12); 2695–703. ©2015 AACR." @default.
• W2131232783 created "2016-06-24" @default.
• W2131232783 creator A5003433691 @default.
• W2131232783 creator A5007992309 @default.
• W2131232783 creator A5019995834 @default.
• W2131232783 creator A5024805130 @default.
• W2131232783 creator A5030525690 @default.
• W2131232783 creator A5033935955 @default.
• W2131232783 creator A5039567364 @default.
• W2131232783 creator A5058291433 @default.
• W2131232783 creator A5063955723 @default.
• W2131232783 creator A5064953304 @default.
• W2131232783 creator A5069507396 @default.
• W2131232783 creator A5078259926 @default.
• W2131232783 creator A5079633934 @default.
• W2131232783 creator A5089429821 @default.
• W2131232783 date "2015-06-14" @default.
• W2131232783 modified "2023-10-10" @default.
• W2131232783 title "A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors" @default.
• W2131232783 cites W1973569665 @default.
• W2131232783 cites W1976646890 @default.
• W2131232783 cites W1979740016 @default.
• W2131232783 cites W1981017716 @default.
• W2131232783 cites W1987662957 @default.
• W2131232783 cites W2009944998 @default.
• W2131232783 cites W2014016903 @default.
• W2131232783 cites W2030370645 @default.
• W2131232783 cites W2040827891 @default.
• W2131232783 cites W2051319925 @default.
• W2131232783 cites W2056296460 @default.
• W2131232783 cites W2064667094 @default.
• W2131232783 cites W2065820769 @default.
• W2131232783 cites W2067984208 @default.
• W2131232783 cites W2068675926 @default.
• W2131232783 cites W2073143902 @default.
• W2131232783 cites W2102394111 @default.
• W2131232783 cites W2117748018 @default.
• W2131232783 cites W2123696077 @default.
• W2131232783 cites W2123931003 @default.
• W2131232783 cites W2126959323 @default.
• W2131232783 cites W2128295200 @default.
• W2131232783 cites W2130550234 @default.
• W2131232783 cites W2137478221 @default.
• W2131232783 cites W2145967409 @default.
• W2131232783 cites W2150455500 @default.
• W2131232783 cites W2153293603 @default.
• W2131232783 cites W2157930949 @default.
• W2131232783 cites W2160947862 @default.
• W2131232783 cites W2586446119 @default.
• W2131232783 doi "https://doi.org/10.1158/1078-0432.ccr-14-2797" @default.
• W2131232783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25724527" @default.
• W2131232783 hasPublicationYear "2015" @default.
• W2131232783 type Work @default.
• W2131232783 sameAs 2131232783 @default.
• W2131232783 citedByCount "119" @default.
• W2131232783 countsByYear W21312327832015 @default.
• W2131232783 countsByYear W21312327832016 @default.
• W2131232783 countsByYear W21312327832017 @default.
• W2131232783 countsByYear W21312327832018 @default.
• W2131232783 countsByYear W21312327832019 @default.
• W2131232783 countsByYear W21312327832020 @default.
• W2131232783 countsByYear W21312327832021 @default.
• W2131232783 countsByYear W21312327832022 @default.
• W2131232783 countsByYear W21312327832023 @default.
• W2131232783 crossrefType "journal-article" @default.
• W2131232783 hasAuthorship W2131232783A5003433691 @default.
• W2131232783 hasAuthorship W2131232783A5007992309 @default.
• W2131232783 hasAuthorship W2131232783A5019995834 @default.
• W2131232783 hasAuthorship W2131232783A5024805130 @default.
• W2131232783 hasAuthorship W2131232783A5030525690 @default.
• W2131232783 hasAuthorship W2131232783A5033935955 @default.
• W2131232783 hasAuthorship W2131232783A5039567364 @default.
• W2131232783 hasAuthorship W2131232783A5058291433 @default.
• W2131232783 hasAuthorship W2131232783A5063955723 @default.
• W2131232783 hasAuthorship W2131232783A5064953304 @default.
• W2131232783 hasAuthorship W2131232783A5069507396 @default.
• W2131232783 hasAuthorship W2131232783A5078259926 @default.
• W2131232783 hasAuthorship W2131232783A5079633934 @default.
• W2131232783 hasAuthorship W2131232783A5089429821 @default.
• W2131232783 hasBestOaLocation W21312327832 @default.
• W2131232783 hasConcept C112705442 @default.
• W2131232783 hasConcept C126322002 @default.
• W2131232783 hasConcept C197934379 @default.
• W2131232783 hasConcept C2780580376 @default.
• W2131232783 hasConcept C2780852908 @default.
• W2131232783 hasConcept C71924100 @default.
• W2131232783 hasConcept C90924648 @default.
• W2131232783 hasConceptScore W2131232783C112705442 @default.
• W2131232783 hasConceptScore W2131232783C126322002 @default.
• W2131232783 hasConceptScore W2131232783C197934379 @default.
• W2131232783 hasConceptScore W2131232783C2780580376 @default.
• W2131232783 hasConceptScore W2131232783C2780852908 @default.
• W2131232783 hasConceptScore W2131232783C71924100 @default.
• W2131232783 hasConceptScore W2131232783C90924648 @default.
• W2131232783 hasIssue "12" @default.
• W2131232783 hasLocation W21312327831 @default.
• W2131232783 hasLocation W21312327832 @default.
• W2131232783 hasLocation W21312327833 @default.

• next